Quince Therapeutics, Inc. (QNCX) Stock
QNCX Key Statistics
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
CEO: Dirk Thye. Company website
QNCX — Frequently Asked Questions
What is the QNCX stock price today?
Quince Therapeutics, Inc. (QNCX) trades at $35.66, up 21.46% on the day, as of Nov 12, 2026 09:38 UTC.
What is Quince Therapeutics, Inc.'s market cap?
Quince Therapeutics, Inc. has a market capitalisation of $198.56M, calculated from the live QNCX share price and shares outstanding.
What is the P/E ratio of QNCX?
QNCX has no meaningful price-to-earnings ratio: Quince Therapeutics, Inc. lost $16.80 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Quince Therapeutics, Inc. make?
Quince Therapeutics, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for QNCX?
QNCX has traded between $16.00 and $76.80 over the past 52 weeks, and the last price is 53.6% below that high.
Is Quince Therapeutics, Inc. profitable?
Yes. Quince Therapeutics, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for QNCX?
Wall Street analysts rate QNCX Hold.
What sector is Quince Therapeutics, Inc. in?
Quince Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Quince Therapeutics, Inc.?
Dirk Thye is the chief executive of Quince Therapeutics, Inc., which employs 36 people.
Where can I track QNCX in real time?
QFI Terminal shows QNCX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See QNCX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open QNCX in Terminal See plans